Developed from a comprehensive literature review and expert consensus, this document is fully dedicated to conservative and medical management.
While surgical innovations are thriving, it is essential to remember that first-line management of BPH remains non-interventional. These practical guidelines emphasize that watchful-waiting is appropriate for men with non-bothersome LUTS, and that lifestyle and dietary advice should be offered to all men presenting with LUTS!
For patients with bothersome symptoms, alpha-blockers remain the cornerstone of initial therapy, while 5ARI, antimuscarinics, and beta-agonists should be offered, if necessary, in second-line treatment. These guidelines also review all medical options, including IPDE5, phytotherapy, and all associations available.
The aim of this work is to provide a clear, up-to-date reference for current and daily practice.
Written by: Julien Anract,1 Clément Klein,2 Clément Sarrazin,3 Ugo Pinar,4 Armand Chevrot,5 Hakim Fassi-Fehri,6 Jonas Wilisch,7 Jérôme Gas,8 Yohann Rouscoff,9 Emmanuel Della Negra,10 Steeve Doizi,11 Souhil Lebdai,12
- Urology Department, Hôpital Cochin, Paris, France.
- Urology Department, CHU de Bordeaux, Bordeaux, France.
- Urology Department, Pitié-Salpêtrière, Paris, France.
- Urology Department, CHU de Grenoble, Grenoble, France.
- Urology Department, Clinique Rhône Durance, Avignon, France.
- Urology Department, Hospice Civils de Lyon, Lyon, France.
- Urology Department, Hôpital Privé Natecia, Lyon, France.
- Urology Department, Clinique du Pont de Chaumes, Montauban, France.
- Urology Department, Polyclinique Saint-Georges, Nice, France.
- Urology Department, Hôpital des Côtes d'Armor, Saint-Brieuc, France.
- Urology Department, Hôpital Tenon, Paris, France.
- Urology Department, CHU d'Angers, Angers, France.